| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078 | CRIS | Phase 1, Phase 2 | Recruiting | 2027-07Estimated |
| Oral Ifetroban in Subjects With Duchenne Muscular DystrophyNCT03340675 | Cumberland Pharmaceuticals | Phase 2 | Completed | 2024-03-06Actual |
| Phase 2 Dose-finding IMU-838 for Ulcerative ColitisNCT03341962 | Immunic AG | Phase 2 | Terminated | 2022-11-16Actual |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)NCT03363841 | SCYX | Phase 3 | Completed | 2023-04-14Actual |
| Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaNCT03364231 | TGTX | Phase 2 | Completed | 2022-02-15Actual |
| Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisNCT03368118 | ABVX | Phase 2 | Completed | 2022-07-12Actual |
| Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaNCT03373201 | Vanda Pharmaceuticals | Phase 3 | Completed | 2018-03-05Actual |
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaNCT03377179 | RedHill Biopharma Limited | Phase 2 | Completed | 2022-06-21Actual |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)NCT03377491 | NVCR | Phase 3 | Completed | 2024-10-16Actual |
| CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRSNCT03401190 | CALC | Phase 2 | Completed | 2019-02-14Actual |
| A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT03404115 | ALDX | Phase 2 | Completed | 2018-07-11Actual |
| Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034 | Cardiff Oncology | Phase 2 | Completed | 2023-10-16Actual |
| Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) InfectionNCT03421743 | SVRA | Phase 2 | Completed | 2019-10-15Actual |
| Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060 | AKARI Therapeutics | Phase 2 | Completed | 2018-11-15Actual |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisNCT03427125 | Ardelyx | Phase 3 | Completed | 2019-11-15Actual |
| Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive KeratoconusNCT03442751 | Glaukos Corporation | Phase 3 | Completed | 2019-11-01Actual |
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsNCT03459287 | Cerus Corporation | Phase 3 | Completed | 2023-12-04Actual |
| Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaNCT03469934 | ANAB | Phase 2 | Completed | 2018-10-30Actual |
| A Long Term Safety Study of BCX7353 in Hereditary AngioedemaNCT03472040 | BioCryst Pharmaceuticals | Phase 2, Phase 3 | Completed | 2022-04-27Actual |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisNCT03482752 | SVRA | Phase 3 | Terminated | 2021-01-14Actual |
| Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the KneeNCT03485157 | MDXG | Phase 2 | Completed | 2022-04-19Actual |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerNCT03485729 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2023-01-19Actual |
| Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAENCT03485911 | BioCryst Pharmaceuticals | Phase 3 | Completed | 2019-04-10Actual |
| Cantharidin and Occlusion in Verruca EpitheliumNCT03487549 | VRCA | Phase 2 | Completed | 2019-05-16Actual |
| Open Label Extension Study of AMX0035 in Patients With ALSNCT03488524 | AMLX | Phase 2 | Completed | 2021-03-01Actual |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)NCT03493685 | TVTX | Phase 3 | Completed | 2023-03-20Actual |
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisNCT03494504 | ALDX | Phase 3 | Completed | 2018-11-05Actual |
| PRISM Study-Pruritus Relief Through Itch Scratch ModulationNCT03497975 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2022-05-10Actual |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2NCT03499795 | Inovio Pharmaceuticals | Phase 2 | Completed | 2020-06-16Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790 | Cognition Therapeutics | Phase 2 | Completed | 2024-05-29Actual |
Trial details
- Registry ID
- NCT03328078
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT03340675
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03341962
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03363841
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03364231
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03368118
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03373201
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03377179
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03377491
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03401190
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03404115
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03414034
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03421743
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03427060
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03427125
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03442751
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03459287
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03469934
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03472040
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03482752
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03485157
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03485729
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03485911
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03487549
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03488524
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03493685
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03494504
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03497975
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03499795
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03507790
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.